Heparin-Associated Polypeptides and Uses Thereof

Abstract

Described herein are therapeutic compositions comprising heparin-associated polypeptides useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . A method for treating a muscle degeneration in a subject, comprising the steps of: selecting the subject for treatment; administering to the subject a therapeutically effective amount of a pro-regenerative factor, whereby a muscle degeneration in the subject is decreased. 
     
     
         22 . The method of  claim 21 , wherein the muscle degeneration is a muscle wasting disorder, an aging disorder, a muscle dystrophy, a muscle atrophy, or a muscle injury. 
     
     
         23 . The method of  claim 21 , wherein the muscle degeneration is caused by an acute injury. 
     
     
         24 . The method of  claim 21 , wherein the muscle degeneration is caused by atrophy. 
     
     
         25 . The method of  claim 21 , wherein the muscle degeneration is caused by a sarcopenia. 
     
     
         26 . The method of  claim 21 , wherein the muscle degeneration is caused by a muscle dystrophy. 
     
     
         27 . The method of  claim 21 , wherein the pro-regenerative factor is a THBS1, a FGF17, an IGF2, a BMP7, a VTN, an THBS4, an IGFBP7, a POSTN, or a PDGFRL. 
     
     
         28 . The method of  claim 27 , wherein the pro-regenerative factor is a THBS1. 
     
     
         29 . The method of  claim 27 , wherein the pro-regenerative factor is an FGF17. 
     
     
         30 . The method of  claim 27 , wherein the pro-regenerative factor is a BMP7. 
     
     
         31 . The method of  claim 27 , wherein the pro-regenerative factor is an IGF2. 
     
     
         32 . The method of  claim 27 , wherein the pro-regenerative factor is an IGFBP7. 
     
     
         33 . The method of  claim 27 , wherein the pro-regenerative factor is a POSTN. 
     
     
         34 . The method of  claim 27 , wherein the pro-regenerative factor is a PDGFRL. 
     
     
         35 . The method of  claim 21 , the subject is aged. 
     
     
         36 . The method of  claim 35 , wherein the subject is at least 70 years old. 
     
     
         37 . The method of  claim 36 , wherein the subject has low muscle mass as measured by a DXA, a low gait speed, a SPPB score less than or equal to nine, or weighs less than 35 kg. 
     
     
         38 . The method of  claim 37 , wherein the subject has low muscle mass as measured by at least two of the following: a DXA, a low gait speed, a SPPB score less than or equal to nine, or weighs less than 35 kg. 
     
     
         39 . The method of  claim 37 , wherein the subject has low muscle mass as measured by a DXA, a low gait speed, a SPPB score less than or equal to nine, and weighs less than 35 kg. 
     
     
         40 . The method of  claim 21 , wherein the pro-regenerative factor is administered continuously, once a day, once every two days, once every three days, weekly, biweekly, or monthly.